MAP2K7 and acute myeloid leukemia: To determine which compounds may be effective in AML cells treated in combination with a STAT5 inhibitor, we focused on inhibitors expected to elicit synergistic cytotoxic effects in combination treatments based on previous studies with BMI1, FLT3, MCL1, and MEK inhibitors [17,18,19,20].